A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).

An open-label phase II study, investigating toxicity, treatment efficacy and the local tumor control rate in 69 patients with centrally located tumors and in 69 patients with ultra-centrally located tumors in the lung. Treatment and patient outcomes will be recorded. Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation. Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.

Trial Details

NCT ID
NCT05354596
Phase
NA
Sponsor
Rigshospitalet, Denmark
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • STRICT LUNG
  • STAR LUNG
Locations (sample)
  • Aalborg, Denmark|57.048,9.9187
  • Aarhus, Denmark|56.15674,10.21076
  • Copenhagen, Denmark|55.67594,12.56553
  • Herlev, Denmark|55.72366,12.43998
  • Odense, Denmark|55.39594,10.38831

Key Eligibility Criteria

  • Histology or cytology proven non-hematological cancer or known cancer with local progressive recurrence.
  • ECOG performance status ≤ 2.
  • Age \> 18 years old. • Life expectancy \> 6 months.
  • Maximum one central tumor with the diameter ≤ 5 cm or \> 1 adjacent located tumors with a summarized diameter (measured from the outer margin from …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →